SCOPE

In an interview with ACT editor Andy Studna at SCOPE, Corrigan discusses what YPrime is doing to address challenges in clinical trials and results from the company's recently released eCOA report.

In an interview with ACT editor Andy Studna at SCOPE, Deyle, VP & GM, Clinical Research, Flatiron Health discusses real-world evidence in clinical trials.

In an interview with ACT editor Andy Studna at SCOPE, Young, Chief Science Officer, CluePoints discusses where the industry is currently adopting RBQM and the level of comfort that comes with it.

In an interview with ACT editor Andy Studna at SCOPE, Everhart, MD, FACP, clinical vice president, internal medicine, Signant Health discusses decentralized trials and how they may be increasing site burden.

In an interview with ACT editor Andy Studna at SCOPE, Morahan, senior director, clinical data analytics, IQVIA Technologies discusses how AI can advance trial execution and what stakeholders should be keeping top of mind when choosing technology vendors.

Breakout session at SCOPE Summit 2024 discusses the potential use of artificial intelligence to improve clinical trial strategy generation.

Interactive panel at SCOPE discussed the potential of utilizing artificial intelligence in clinical trials.

A summary of this year’s key topics and discussions.

Highlights from the annual SCOPE conference held in Orlando, FL.

Melissa Easy, VP and GM, clinical technologies at IQVIA speaks about concerns with clinical technology at the SCOPE 2023 conference in Orlando, FL.

Melissa Easy, VP and GM, clinical technologies at IQVIA speaks about what should be top of mind for clinops professionals in 2023 at the SCOPE 2023 conference in Orlando, FL.

Len Rosenberg, head of clinical operations at Beat AML, discusses the outcome of his company's study, which was four years in the making.

Sunny Kumar, MD, partner at GSR Ventures speaks about reducing hospital readmissions for high-risk patients at the SCOPE 2023 conference in Orlando, FL.

Sunny Kumar, MD, partner at GSR Ventures speaks about venture capital in clinical research at the SCOPE 2023 conference in Orlando, FL.

Joan Chambers, senior director of marketing, communication & education at CISCRP notes her key takeaways from the SCOPE 2023 conference in Orlando, FL.

Joan Chambers, senior director of marketing, communication & education for CISCRP reveals what innovations are coming up at the SCOPE 2023 conference in Orlando, FL.

Joan Chambers, senior director of marketing, communication & education for CISCRP comments on current CISCRP happenings at the SCOPE 2023 conference in Orlando, FL.

Joan Chambers, senior director of marketing, communication & education for CISCRP names the three biggest challenges facing clinical trials at the SCOPE 2023 conference in Orlando, FL.

Hope Meely, chief clinical officer at Slope, provides a brief summary of her SCOPE presentation revolving around biospecimen collection.

Hope Meely, chief clinical officer at Slope, discusses the feedback she received following her SCOPE presentation around biospecimen collection.

Murray L. Aitken, SVP of IQVIA offers insights that small biopharma organizations can take away from larger companies at the SCOPE 2023 conference in Orlando, FL.

Hope Meely, chief clinical officer at Slope, offers a look into what she believes is the most important clinical trial development over the past five years.

Sunny Kumar, MD, partner at GSR Ventures speaks about how healthcare and clinical trials can work together to create a greater impact at the SCOPE 2023 conference in Orlando, FL.

Len Rosenberg, head of clinical operations at Beat AML, reflects on the issues that come with finding patients durable treatment plans.

Len Rosenberg, head of clinical operations at Beat AML, comments on how factors, such as proper data collection and reporting techniques, can prove to be efficient and help save lives.

Len Rosenberg, head of clinical operations at Beat AML, comments on how his company not helps to advance the sector, but integrates new ways to conduct clinical trials.

Murray L. Aitken, SVP of IQVIA speaks about the concerns of smaller biopharma companies getting into clinical trials at the SCOPE 2023 conference in Orlando, FL.

Seagen, an oncology biotech, emphasizes personalization as part of its DE&I strategy.